{"PubmedBookArticle": [], "PubmedArticle": [{"MedlineCitation": {"SpaceFlightMission": [], "CitationSubset": ["IM"], "OtherAbstract": [], "KeywordList": [], "GeneralNote": [], "OtherID": [], "InvestigatorList": [], "PMID": "29578432", "DateCompleted": {"Year": "2018", "Month": "12", "Day": "21"}, "DateRevised": {"Year": "2022", "Month": "12", "Day": "07"}, "Article": {"ArticleDate": [], "Language": ["eng"], "ELocationID": [], "Journal": {"ISSN": "1512-0112", "JournalIssue": {"Issue": "Issue", "PubDate": {"Year": "2018", "Month": "Feb"}}, "Title": "Georgian medical news", "ISOAbbreviation": "Georgian Med News"}, "ArticleTitle": "TREATMENT OF PYOINFLAMMATORY COMPLICATIONS WITH INDIVIDUALLY SELECTED OZONE DOSE IN PATIENTS WITH DIABETES.", "Pagination": {"StartPage": "91", "EndPage": "94", "MedlinePgn": "91-94"}, "Abstract": {"AbstractText": ["The severity of purulent-inflammatory process in patients with diabetes mellitus is determined by lymphocytotoxic test. The test shows that application of intravenous ozone therapy with individually selected ozone dose significantly decreases the spread of necrotic suppurative focus already on the third day of treatment. Granulation tissue and marginal epithelization in the wound develops on the 6-8th day of hospitalization; normalization of glycemic levels shorten of the period of the hospital stay up to 3-5 days, compared to the control group."]}, "AuthorList": [{"AffiliationInfo": [{"Identifier": [], "Affiliation": "Higher State Educational Institution of Ukraine \"Bukovinian State Medical University\", Chernivtsi, Ukraine."}], "Identifier": [], "LastName": "Karatieieva", "ForeName": "S", "Initials": "S"}, {"AffiliationInfo": [{"Identifier": [], "Affiliation": "Higher State Educational Institution of Ukraine \"Bukovinian State Medical University\", Chernivtsi, Ukraine."}], "Identifier": [], "LastName": "Makarova", "ForeName": "O", "Initials": "O"}, {"AffiliationInfo": [{"Identifier": [], "Affiliation": "Higher State Educational Institution of Ukraine \"Bukovinian State Medical University\", Chernivtsi, Ukraine."}], "Identifier": [], "LastName": "Yurkiv", "ForeName": "O", "Initials": "O"}, {"AffiliationInfo": [{"Identifier": [], "Affiliation": "Higher State Educational Institution of Ukraine \"Bukovinian State Medical University\", Chernivtsi, Ukraine."}], "Identifier": [], "LastName": "Semenenko", "ForeName": "S", "Initials": "S"}, {"AffiliationInfo": [{"Identifier": [], "Affiliation": "Higher State Educational Institution of Ukraine \"Bukovinian State Medical University\", Chernivtsi, Ukraine."}], "Identifier": [], "LastName": "Berezova", "ForeName": "M", "Initials": "M"}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "Georgia (Republic)", "MedlineTA": "Georgian Med News", "NlmUniqueID": "101218222", "ISSNLinking": "1512-0112"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Anti-Inflammatory Agents"}, {"RegistryNumber": "0", "NameOfSubstance": "Blood Glucose"}, {"RegistryNumber": "0", "NameOfSubstance": "Immunologic Factors"}, {"RegistryNumber": "2679MF687A", "NameOfSubstance": "Niacin"}, {"RegistryNumber": "66H7ZZK23N", "NameOfSubstance": "Ozone"}, {"RegistryNumber": "9005-49-6", "NameOfSubstance": "Heparin"}, {"RegistryNumber": "F5TD010360", "NameOfSubstance": "Alprostadil"}, {"RegistryNumber": "SD6QCT3TSU", "NameOfSubstance": "Pentoxifylline"}], "MeshHeadingList": [{"QualifierName": ["therapeutic use"], "DescriptorName": "Alprostadil"}, {"QualifierName": ["methods"], "DescriptorName": "Amputation, Surgical"}, {"QualifierName": ["therapeutic use"], "DescriptorName": "Anti-Inflammatory Agents"}, {"QualifierName": ["drug effects", "metabolism"], "DescriptorName": "Blood Glucose"}, {"QualifierName": ["blood", "drug therapy", "pathology", "surgery"], "DescriptorName": "Diabetes Mellitus"}, {"QualifierName": ["blood", "drug therapy", "pathology", "surgery"], "DescriptorName": "Diabetic Foot"}, {"QualifierName": [], "DescriptorName": "Drug Administration Schedule"}, {"QualifierName": ["therapeutic use"], "DescriptorName": "Heparin"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["therapeutic use"], "DescriptorName": "Immunologic Factors"}, {"QualifierName": ["therapeutic use"], "DescriptorName": "Niacin"}, {"QualifierName": ["therapeutic use"], "DescriptorName": "Ozone"}, {"QualifierName": ["therapeutic use"], "DescriptorName": "Pentoxifylline"}, {"QualifierName": ["blood", "drug therapy", "pathology", "surgery"], "DescriptorName": "Suppuration"}]}, "PubmedData": {"ReferenceList": [], "History": [{"Year": "2018", "Month": "3", "Day": "27", "Hour": "6", "Minute": "0"}, {"Year": "2018", "Month": "3", "Day": "27", "Hour": "6", "Minute": "0"}, {"Year": "2018", "Month": "12", "Day": "24", "Hour": "6", "Minute": "0"}], "PublicationStatus": "ppublish", "ArticleIdList": ["29578432"]}}]}